MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas.

Posch, Christian; Sanlorenzo, Martina; Ma, Jeffrey; Kim, Sarasa T; Zekhtser, Mitchell; Ortiz-Urda, Susana

Posch, Christian; Sanlorenzo, Martina; Ma, Jeffrey; Kim, Sarasa T; Zekhtser, Mitchell; Ortiz-Urda, Susana.

Afiliación

Posch C; Technical University of Munich, Department of Dermatology and Allergy, 80802 Munich, Germany.
Sanlorenzo M; University of California San Francisco, Department of Dermatology, Mt. Zion Cancer Research Center, 94115 San Francisco, USA.
Ma J; Faculty of Medicine, Sigmund Freud University, 1020, Vienna, Austria.
Kim ST; University of California San Francisco, Department of Dermatology, Mt. Zion Cancer Research Center, 94115 San Francisco, USA.
Zekhtser M; Institute of Cancer Research, Medical University of Vienna, 1090 Vienna, Austria.
Ortiz-Urda S; University of California San Francisco, Department of Dermatology, Mt. Zion Cancer Research Center, 94115 San Francisco, USA.

Oncotarget ; 9(79): 34990-34995, 2018 Oct 09.

Article en En | MEDLINE | ID: mdl-30405888

Palabras clave

BRAF; CDK4; MEK; NRAS; melanoma

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google